Proving Device Incubation Works: An Interview with The Foundry
Executive Summary
A decade ago, incuabators were seen as the best medicine for what then ailed the medical device industry, most notably a complex regulatory pathway and a difficult venture financing climate. Perhaps not surprisingly, as both the regulatory path and venture financing grew easier in the mid 2000s, incubators began to struggle, victims of their own financing problems. More recently, two huge acquisitions, Abbott's purchase of Evalve and Medtronic's of Ardian, suggest that at least one incubator, The Foundry, is proving that incubation works.
You may also be interested in...
Foundry Founders Take Stock
Hanson Gifford III and Mark Deem, two co-founders of the prolific medtech incubator The Foundry, have had a hand in generating more than $2 billion in value for medtech investors and entrepreneurs during the incubator’s 15-plus years. At IN³ Medical Device 360° in Dublin, the pair shared some of the lessons they have learned along the way.
Foundry Founders Take Stock
Hanson Gifford III and Mark Deem, two co-founders of the prolific medtech incubator The Foundry, have had a hand in generating more than $2 billion in value for medtech investors and entrepreneurs over the incubator’s 15-plus years. At IN3 Dublin, the pair shared some of the lessons they have learned along the way.
Miramar Labs: Bringing A Traditional Device Model To Aesthetics
Miramar is employing a conventional product development strategy to create the first device therapy in an unconventional clinical space – hyperhidrosis, or excessive sweating. The key: a more rigorous clinical approach than usual in aesthetics. But is the market there?